fingolimod hydrochloride has been researched along with Cancer of Nasopharynx in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Li, N; Li, W; Ni, B; Ruan, Z; Tian, Z; Wang, H; Wang, Y; Zhang, K | 1 |
1 other study(ies) available for fingolimod hydrochloride and Cancer of Nasopharynx
| Article | Year |
|---|---|
Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemoradiotherapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Fingolimod Hydrochloride; Humans; Ki-67 Antigen; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2016 |